Chromocell Therapeutics Corporation (CHRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chromocell Therapeutics Corporation (CHRO) has a cash flow conversion efficiency ratio of 0.069x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-447.14K) by net assets ($-6.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CHRO net asset quality score to measure how much of total assets are equity-financed.
Chromocell Therapeutics Corporation - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Chromocell Therapeutics Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Chromocell Therapeutics Corporation debt service capacity to assess how comfortably operating cash covers total debt obligations.
Chromocell Therapeutics Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chromocell Therapeutics Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aqua Metals Inc
NASDAQ:AQMS
|
-0.293x |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
0.385x |
|
Kore Mining Ltd
V:KORE
|
0.029x |
|
Tay Ninh Cable Car Tour Co.
VN:TCT
|
-0.003x |
|
Raytech Holding Limited Ordinary Shares
NASDAQ:RAY
|
0.013x |
|
Kumpulan Jetson Bhd
KLSE:9083
|
0.044x |
|
Chuan Huat Resources Bhd
KLSE:7016
|
-0.039x |
|
Auga Group AB
STU:W9Z
|
0.032x |
Annual Cash Flow Conversion Efficiency for Chromocell Therapeutics Corporation (2020–2024)
The table below shows the annual cash flow conversion efficiency of Chromocell Therapeutics Corporation from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see Chromocell Therapeutics Corporation market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-2.71 Million | $-5.79 Million | 2.134x | +1302.03% |
| 2023-12-31 | $-6.44 Million | $-981.03K | 0.152x | 0.00% |
| 2023-09-30 | $-6.44 Million | $-981.03K | 0.152x | -64.00% |
| 2022-12-31 | $-3.71 Million | $-1.57 Million | 0.423x | 0.00% |
| 2022-09-30 | $-3.71 Million | $-1.57 Million | 0.423x | -2.32% |
| 2021-12-31 | $-3.68 Million | $-1.59 Million | 0.433x | 0.00% |
| 2021-09-30 | $-3.68 Million | $-1.59 Million | 0.433x | -57.29% |
| 2020-12-31 | $-3.58 Million | $-3.63 Million | 1.013x | 0.00% |
| 2020-09-30 | $-3.58 Million | $-3.63 Million | 1.013x | -- |
About Chromocell Therapeutics Corporation
Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and id… Read more